+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2017-06-20Number of Pages: 163

Non-opioid Pain Patch Market (Patch Type - Lidocaine Patches, Diclofenac Patches, Methyl Salicylate Patches, Capsaicin Patches, Ketoprofen Patches; Distribution Channel - Hospital Pharmacies, Online Pharmacies, and Independent Pharmacies and Drug Stores) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Global Non-opioid Pain Patch Market: Snapshot

The increasing epidemic of opioid abuse and misuse has necessitated the use of safer, non-addicting analgesics to relive pain. Acute/chronic pain is among the most common complaints that patients seek emergency medical care for. According to the U.S. National Prescription Audit, opioid prescriptions dispended by retail pharmacies increased from 76 million in 1997 to 219 million in 2011.

The reduction in opioid prescriptions is estimated to result in increased usage of non-opioid therapeutics for treating pain thereby driving expansion of the non-opioid pain patch market. Non-opioid pain patch available in various types are effective for certain types of pain. They are safe and well-tolerated and have little risk of systemic side-effects and drug interactions.

The increasing incidence of pain-related disorders and increasing global spending on pain management treatments is anticipated to positively impact the global non-opioid pain patch market.

On the contrary, low adoption rate of non-opioid pain patch is challenging the growth of this market. This is because oral pain relieving drugs act in a short duration of time and act directly on the central nervous system thus preventing the pain sensation. The increasing success of implants for long-term pain relief is also detrimental to the non-opioid pain patch market. These minimally invasive procedures deliver excellent clinical success and have been acting as long-term pain relief solution for patients globally.

The global non-opioid pain patch market stood at US$3,750 mn in 2015 and is expected to reach a valuation of US$4,983.3 mn by 2024 rising at a CAGR of 3.3% between 2016 and 2024.

non opioid pain patch market

 

Methyl Salicylate Patch Type Segment to Display Significant Growth Rate in Future

In terms of patch type, the non-opioid pain patch market is segmented into lidocaine patches, methyl salicylate patches, ketoprofen patches, diclofenac patches, capsaicin patches, and others. Among these, the segment of lidocaine patches led the non-opioid pain patch market in 2015; however, due to patent expiration of lidocaine patch and availability of generic substitutes, this segment is expected to display a declined growth rate. On the other hand, the segment of methyl salicylate is expected to rise at a significant CAGR during the forecast period. The growth of this segment is attributed to faster pain relief, efficient drug delivery for prolonged duration, and increasing number of manufacturers.

On the basis of distribution channel, the global non-opioid pain patch market is segmented into hospital pharmacies, independent pharmacies, online pharmacies, and drug stores.

Asia Pacific to Emerge as Significant Market

In terms of geography, the non-opioid pain patch market is classified into North America, Asia Pacific, Europe, Latin America, and the Middle East and Africa. Among these, North America led the global non-opioid pain patch market in 2015 and is expected to account for a massive 51.5% of the overall market by 2024. According to statistics of the global Burden of Disease, in 2014, back pain was ranked amongst the top ten diseases and injuries that led to death across the world, with the U.S. leading amongst all. Healthcare services in the U.S. spend about US$ 50 bn every year due to back pain related concerns.

Asia Pacific is expected to emerge as a significant market for non-opioid pain patch expanding at a CAGR of 3.5% between 2016 and 2024.

Some of the key companies in the global non-opioid pain patch market are Acorda Therapeutics Inc., ALLERGAN, GlaxoSmithKline plc, IBSA Institut Biochimque SA, Pfizer Inc., Teikoku seiyaku Co. Ltd., Endo International plc, Hisamitsu Pharmaceutical Co. Inc., Mylan N.V., and TEH SENG Pharmaceutical Mfg Co. Ltd among others. 

Global Non-opioid Pain Patch Market: Overview

Transdermal drug delivery systems (TDDS) is a systemic drug therapy approach which eliminates the risk of gastro-intestinal adverse reactions. The low concentrations of drugs are delivered using these systems as first pass metabolism in the liver is bypassed by using them. The non-opioid pain patch market is witnessing a steady growth due to stable adoption rates. Currently there are three generations of the transdermal drug delivery systems in the market, out of which majority of the FDA approved patches belong to first-generation products. Non-opioid pain patches offer efficient transdermal drug delivery option for the treatment of various pain conditions for a prolonged period of time. The non-opioid pain patches have various functional features such as occlusive backing film prevents inadvertent drug loss, and also improves drug penetration, the protective drug release liner maintains the patch integrity, and prevents accidental exposure before its application.

The market overview section of the report comprises qualitative analysis of the overall non-opioid pain patch market considering the factors determining the market dynamics such as drivers, restraints and opportunities, along with Porter’s five force analysis and market attractiveness analysis. In addition, such as market opportunity analysis for the patch type, and distribution channels, and key industry developments has also been provided. Key industry developments include the major events occurred in past decade and are expected to occur during the forecast period which are likely to affect the market dynamics. The WHO pain ladder for pain management treatment has also been provided, along with the percentage prevalence rates of acute pain by region as well as by countries. The snapshot of patch design technologies has been given in the market overview section.

Global Non-opioid Pain Patch Market: Market Segmentation

The global non-opioid pain patch market has been segmented on the basis of patch type, and distribution channels. In terms of patch type, the global non-opioid pain patch market is divided into lidocaine patches, diclofenac patches, methyl salicylate patches, capsaicin patches, ketoprofen patches, and others. Furthermore, on the basis of distribution channels, the global non-opioid pain patch market has been classified as hospital pharmacies, online pharmacies, and independent pharmacies & drug stores. The market for these patch type, and distribution channels has been extensively analyzed on the basis of factors such as non-opioid patch usage pattern, sales revenue, geographic presence and technological developments. The market size and forecast in terms of revenue (US$ million) for each of these segments have been provided for the period 2014 to 2024, considering 2015 as the base year. The report also provides the compounded annual growth rate (CAGR) for each segment for the forecast period 2016 to 2024.

Geographically, the non-opioid pain patch market has been classified into five segments namely, North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The market size and forecast for each region has been provided for the period 2014 to 2024, in terms of patch type, and distribution channels, along with the CAGR (%) for the forecast period 2016 to 2024.

Global Non-opioid Pain Patch Market: Competitive Landscape

The report also provides a section on the competitive landscape, wherein the market share analysis of leading players in the global non-opioid pain patch market, in terms of percentage share in 2016 (expected) has been discussed. A list of recommendations has also been included for new entrants as well as existing market players to help them establish a strong presence in the market and increase their market share. The report concludes with the profiles of major players in the global non-opioid pain patch market such as Acorda Therapeutics, Inc., ALLERGAN, Endo International plc, GlaxoSmithKline plc, Hisamitsu Pharmaceutical Co.,Inc., IBSA Institut Biochimque SA, Mylan N.V. , Pfizer, Inc., TEH SENG Pharmaceutical Mfg. Co., Ltd., and Teikoku Seiyaku Co., Ltd., among others. The major market players are evaluated on various parameters such as company overview, financial overview, product portfolio, business strategies and recent developments.

The global Non-opioid Pain Patch market has been segmented as follows:

  • Global Non-opioid Pain Patch Market, by Non-opioid Pain Patch Type
    • Lidocaine Patches
    • Diclofenac Patches
    • Methyl Salicylate Patches
    • Capsaicin Patches
    • Ketoprofen Patches
    • Others
       
  • Global Non-opioid Pain Patch Market, by Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Independent Pharmacies & Drug Stores
       
  • Global Non-opioid Pain Patch Market, by Geography
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East & Africa


 
 
Back To Top